Identification of an NF1 Microdeletion with Optical Genome Mapping

Int J Mol Sci. 2023 Sep 1;24(17):13580. doi: 10.3390/ijms241713580.

Abstract

Neurofibromatosis type 1 (NF1) is a clinically heterogeneous neurocutaneous disorder inherited in autosomal dominant manner. Approximately 5-10% of the cases are caused by NF1 microdeletions involving the NF1 gene and its flanking regions. Microdeletions, which lead to more severe clinical manifestations, can be subclassified into four different types (type 1, 2, 3 and atypical) according to their size, the genomic location of the breakpoints and the number of genes included within the deletion. Besides the prominent hallmarks of NF1, patients with NF1 microdeletions frequently exhibit specific additional clinical manifestations like dysmorphic facial features, macrocephaly, overgrowth, global developmental delay, cognitive disability and an increased risk of malignancies. It is important to identify the genes co-deleted with NF1, because they are likely to have an effect on the clinical manifestation. Multiplex ligation-dependent probe amplification (MLPA) and microarray analysis are the primary techniques for the investigation of NF1 microdeletions. However, based on previous research, optical genome mapping (OGM) could also serve as an alternative method to identify copy number variations (CNVs). Here, we present a case with NF1 microdeletion identified by means of OGM and demonstrate that this novel technology is a suitable tool for the identification and classification of the NF1 microdeletions.

Keywords: NF1 gene; NF1 microdeletion; OGM; copy number variation; optical genome mapping; structural variation.

Publication types

  • Case Reports

MeSH terms

  • Chromosome Mapping
  • DNA Copy Number Variations
  • Genes, Neurofibromatosis 1
  • Humans
  • Megalencephaly*
  • Neurofibromatosis 1* / genetics

Grants and funding

This work was prepared with the support of the H2020 (SGA No. 739593) grant of the European Union and the National Research, Development and Innovation Fund, financed under the TKP2021-EGA-24 and TKP2021-NVA-15 funding schemes.